Kolon Life Science Inc. (KOSDAQ:102940)
South Korea flag South Korea · Delayed Price · Currency is KRW
14,560
-140 (-0.95%)
Sep 3, 2026, 3:30 PM KST

Kolon Life Science Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
211,439208,982161,387124,639161,584165,485
Other Revenue
--0-0--0-0
211,439208,982161,387124,639161,584165,485
Revenue Growth
17.09%29.49%29.48%-22.86%-2.36%27.87%
Cost of Revenue
153,063153,204144,643112,343124,567128,381
Gross Profit
58,37655,77816,74412,29637,01737,104
Selling, General & Admin
24,22022,73621,13120,14919,58117,696
Research & Development
14,23513,90716,43914,89213,58314,327
Amortization of Goodwill & Intangibles
79.13116.05166.77131.45157.01166.64
Other Operating Expenses
388.91353.78231.77242.57198.91207.68
Operating Expenses
40,00338,20538,82836,39134,37532,855
Operating Income
18,37317,572-22,084-24,0952,6424,249
Interest Expense
-6,649-7,784-7,411-5,857-3,722-6,013
Interest & Investment Income
88.8594.36135.05168.59114.07120.4
Currency Exchange Gain (Loss)
510.4-296.48906.21-348.04-20.33273.77
Other Non Operating Income (Expenses)
8,263-12,056-57,324-312.227,9591,600
EBT Excluding Unusual Items
20,586-2,470-85,779-30,4446,972230.15
Gain (Loss) on Sale of Investments
----14.53-5.1811.07
Gain (Loss) on Sale of Assets
47.71-26.52-1,013-6.9-20.975.12
Asset Writedown
-2,082-1,434-8,855-3,133-2,822-4,327
Pretax Income
35,15525,756-93,086-33,5984,124-4,011
Income Tax Expense
527.03795.76-1.25107.93-2,636
Earnings From Continuing Operations
34,62824,960-93,086-33,5994,016-1,375
Earnings From Discontinued Operations
---2,873-1,883-
Net Income
34,62824,960-93,086-30,7262,133-1,375
Net Income to Common
34,62824,960-93,086-30,7262,133-1,375
Net Income Growth
------
Shares Outstanding (Basic)
131212111111
Shares Outstanding (Diluted)
151412111311
Shares Change
19.97%19.98%4.65%-9.69%10.85%-
EPS (Basic)
2707.652001.49-7794.00-2692.37186.96-120.61
EPS (Diluted)
2403.021824.00-7794.00-2692.37169.00-121.00
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-59,009-28,055-22,279-35,009-27,159-20,600
Free Cash Flow Per Share
-3960.33-1957.83-1865.41-3067.66-2149.14-1807.01
Gross Margin
27.61%26.69%10.38%9.87%22.91%22.42%
Operating Margin
8.69%8.41%-13.68%-19.33%1.64%2.57%
Profit Margin
16.38%11.94%-57.68%-24.65%1.32%-0.83%
Free Cash Flow Margin
-27.91%-13.43%-13.80%-28.09%-16.81%-12.45%
EBITDA
28,58227,335-13,209-15,26412,10915,549
EBITDA Margin
13.52%13.08%-8.18%-12.25%7.49%9.40%
D&A For EBITDA
10,2099,7638,8768,8319,46711,299
EBIT
18,37317,572-22,084-24,0952,6424,249
EBIT Margin
8.69%8.41%-13.68%-19.33%1.64%2.57%
Effective Tax Rate
1.50%3.09%--2.62%-
Advertising Expenses
-389.06409.3153.71300.82